My Onc would like to potentially enroll me in a new Novartis sponsored Tasigna "Discontinuation Study." The name of the study is ENESTfreedom and involves two randomized groups, both of which will discontinue Tasigna, although the second group will delay an additional year prior to discontinuation. The criteria of the study and frequency of PCR testing seems consistent with other studies/discussions. However, in my case, I could end up discontinuing as early as 3 years after diagnosis with only one full year of quarlerly tests >4 log reduction (with the last test prior to discontinuation being >4.5) as defined by the study protocol. This all seems a little early for me since I am currently only 15 months from diagnosis.
At this point, I am interested but not sure of the right questions to be asking. I would appreciate input from the group, especially those that may have already been part of a study. Aside from the medical aspects, most of my immediate concern centers around not wanting to screw anything up with my insurance, especially if I discontinue and then need to re-initiate Tasigna.
Thanks in advance for your input.